IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol
We investigated the striatal dopamine-2 (D2) receptor occupancy caused by different antipsychotic substances in 18 psychotic patients (16 with schizophrenic and two with schizoaffective disorder according to DSM-IV) with single photon emission computed tomography (SPECT) using 123I-iodobenzamide (IB...
Gespeichert in:
| Veröffentlicht in: | Psychopharmacologia 1997-10, Vol.133 (4), p.323-328 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 328 |
|---|---|
| container_issue | 4 |
| container_start_page | 323 |
| container_title | Psychopharmacologia |
| container_volume | 133 |
| creator | KÜFFERLE, B TAUSCHER, J ASENBAUM, S VESELY, C PODREKA, I BRÜCKE, T KASPER, S |
| description | We investigated the striatal dopamine-2 (D2) receptor occupancy caused by different antipsychotic substances in 18 psychotic patients (16 with schizophrenic and two with schizoaffective disorder according to DSM-IV) with single photon emission computed tomography (SPECT) using 123I-iodobenzamide (IBZM) as tracer substance. Four patients were treated with the novel antipsychotic compound quetiapine (300-700 mg/day), six with clozapine (300-600 mg/ day) and eight with haloperidol (10-20 mg/day). They were compared with eight healthy controls. Measurement of S/F ratios and consecutive calculation of D2 receptor occupancy revealed a significantly lower striatal D2 occupancy rate with quetiapine and clozapine in comparison to haloperidol. In correspondence with the low striatal D2 receptor occupancy rates and again in contrast to the haloperidol treatment group, there were no extrapyramidal motor side-effects (EPS) in the quetiapine and clozapine treatment groups. Therefore, the reported data support the position that quetiapine can be considered to be an atypical antipsychotic substance due to its relatively weak striatal D2 receptor blocking property and therefore its low propensity to induce EPS. |
| doi_str_mv | 10.1007/s002130050409 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79417488</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3117819341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c345t-61a1a250c412b68cf68705f58bf75e9af4e492bfd9c5f8c913ef9442cff5aeb43</originalsourceid><addsrcrecordid>eNpdkU-LFDEUxIMo67h69CgEFG-t-TvdfdRh1YUVBdeLl-Z1-mUnSzppk7Syfig_o1lmWNF3eYf6URRVhDzl7BVnrH2dGRNcMqaZYv09suFKikawVtwnG8akbCTX3UPyKOdrVk916oSc9LIVWrIN-X3-9ttH-uXz2e6SuhmuXLii0dJckoMCnk5xgdkFbARNaHApMWXqAl3yjdnH4gxdoDgMJdOSEApO9Kcre1r2SEP8gZ5CKO4vndcxFwgG6fcVi4Olet_6mTgvkFyOgZZIjY-_DhKEie7BxwWTm6J_TB5Y8BmfHP8p-fru7HL3obn49P589-aiMVLp0mw5cBCaGcXFuO2M3XYt01Z3o2019mAVql6MduqNtp3puUTbKyWMtRpwVPKUvDz4LinWoLkMs8sGvYeAcc1D2yveqq6r4PP_wOu4plCzDZLztuO9VLxSzYEyKeac0A5Lqm2nm4Gz4XbF4Z8VK__s6LqOM0539HG2qr846pANeJtqoy7fYaKu3HIt_wD7Gqd-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3117819341</pqid></control><display><type>article</type><title>IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>KÜFFERLE, B ; TAUSCHER, J ; ASENBAUM, S ; VESELY, C ; PODREKA, I ; BRÜCKE, T ; KASPER, S</creator><creatorcontrib>KÜFFERLE, B ; TAUSCHER, J ; ASENBAUM, S ; VESELY, C ; PODREKA, I ; BRÜCKE, T ; KASPER, S</creatorcontrib><description>We investigated the striatal dopamine-2 (D2) receptor occupancy caused by different antipsychotic substances in 18 psychotic patients (16 with schizophrenic and two with schizoaffective disorder according to DSM-IV) with single photon emission computed tomography (SPECT) using 123I-iodobenzamide (IBZM) as tracer substance. Four patients were treated with the novel antipsychotic compound quetiapine (300-700 mg/day), six with clozapine (300-600 mg/ day) and eight with haloperidol (10-20 mg/day). They were compared with eight healthy controls. Measurement of S/F ratios and consecutive calculation of D2 receptor occupancy revealed a significantly lower striatal D2 occupancy rate with quetiapine and clozapine in comparison to haloperidol. In correspondence with the low striatal D2 receptor occupancy rates and again in contrast to the haloperidol treatment group, there were no extrapyramidal motor side-effects (EPS) in the quetiapine and clozapine treatment groups. Therefore, the reported data support the position that quetiapine can be considered to be an atypical antipsychotic substance due to its relatively weak striatal D2 receptor blocking property and therefore its low propensity to induce EPS.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s002130050409</identifier><identifier>PMID: 9372530</identifier><identifier>CODEN: PSYPAG</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Antipsychotic Agents - pharmacokinetics ; Antipsychotic Agents - therapeutic use ; Antipsychotics ; Benzamides ; Biological and medical sciences ; Clozapine ; Clozapine - pharmacokinetics ; Clozapine - therapeutic use ; Computed tomography ; Dibenzothiazepines - pharmacokinetics ; Dibenzothiazepines - therapeutic use ; Dopamine ; Dopamine Antagonists - pharmacokinetics ; Dopamine Antagonists - therapeutic use ; Dopamine D2 receptors ; Extrapyramidal system ; Female ; Haloperidol ; Haloperidol - pharmacokinetics ; Haloperidol - therapeutic use ; Humans ; Male ; Medical sciences ; Middle Aged ; Neostriatum ; Neostriatum - anatomy & histology ; Neostriatum - metabolism ; Neuropharmacology ; Pharmacology. Drug treatments ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Psychosis ; Psychotic Disorders - drug therapy ; Psychotic Disorders - metabolism ; Psychotropic drugs ; Pyrrolidines ; Quetiapine ; Quetiapine Fumarate ; Receptors, Dopamine D2 - metabolism ; Schizophrenia - drug therapy ; Schizophrenia - metabolism ; Single photon emission computed tomography ; Tomography, Emission-Computed, Single-Photon</subject><ispartof>Psychopharmacologia, 1997-10, Vol.133 (4), p.323-328</ispartof><rights>1998 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 1997.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c345t-61a1a250c412b68cf68705f58bf75e9af4e492bfd9c5f8c913ef9442cff5aeb43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2048715$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9372530$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KÜFFERLE, B</creatorcontrib><creatorcontrib>TAUSCHER, J</creatorcontrib><creatorcontrib>ASENBAUM, S</creatorcontrib><creatorcontrib>VESELY, C</creatorcontrib><creatorcontrib>PODREKA, I</creatorcontrib><creatorcontrib>BRÜCKE, T</creatorcontrib><creatorcontrib>KASPER, S</creatorcontrib><title>IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol</title><title>Psychopharmacologia</title><addtitle>Psychopharmacology (Berl)</addtitle><description>We investigated the striatal dopamine-2 (D2) receptor occupancy caused by different antipsychotic substances in 18 psychotic patients (16 with schizophrenic and two with schizoaffective disorder according to DSM-IV) with single photon emission computed tomography (SPECT) using 123I-iodobenzamide (IBZM) as tracer substance. Four patients were treated with the novel antipsychotic compound quetiapine (300-700 mg/day), six with clozapine (300-600 mg/ day) and eight with haloperidol (10-20 mg/day). They were compared with eight healthy controls. Measurement of S/F ratios and consecutive calculation of D2 receptor occupancy revealed a significantly lower striatal D2 occupancy rate with quetiapine and clozapine in comparison to haloperidol. In correspondence with the low striatal D2 receptor occupancy rates and again in contrast to the haloperidol treatment group, there were no extrapyramidal motor side-effects (EPS) in the quetiapine and clozapine treatment groups. Therefore, the reported data support the position that quetiapine can be considered to be an atypical antipsychotic substance due to its relatively weak striatal D2 receptor blocking property and therefore its low propensity to induce EPS.</description><subject>Adult</subject><subject>Antipsychotic Agents - pharmacokinetics</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotics</subject><subject>Benzamides</subject><subject>Biological and medical sciences</subject><subject>Clozapine</subject><subject>Clozapine - pharmacokinetics</subject><subject>Clozapine - therapeutic use</subject><subject>Computed tomography</subject><subject>Dibenzothiazepines - pharmacokinetics</subject><subject>Dibenzothiazepines - therapeutic use</subject><subject>Dopamine</subject><subject>Dopamine Antagonists - pharmacokinetics</subject><subject>Dopamine Antagonists - therapeutic use</subject><subject>Dopamine D2 receptors</subject><subject>Extrapyramidal system</subject><subject>Female</subject><subject>Haloperidol</subject><subject>Haloperidol - pharmacokinetics</subject><subject>Haloperidol - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neostriatum</subject><subject>Neostriatum - anatomy & histology</subject><subject>Neostriatum - metabolism</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychosis</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Psychotic Disorders - metabolism</subject><subject>Psychotropic drugs</subject><subject>Pyrrolidines</subject><subject>Quetiapine</subject><subject>Quetiapine Fumarate</subject><subject>Receptors, Dopamine D2 - metabolism</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - metabolism</subject><subject>Single photon emission computed tomography</subject><subject>Tomography, Emission-Computed, Single-Photon</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkU-LFDEUxIMo67h69CgEFG-t-TvdfdRh1YUVBdeLl-Z1-mUnSzppk7Syfig_o1lmWNF3eYf6URRVhDzl7BVnrH2dGRNcMqaZYv09suFKikawVtwnG8akbCTX3UPyKOdrVk916oSc9LIVWrIN-X3-9ttH-uXz2e6SuhmuXLii0dJckoMCnk5xgdkFbARNaHApMWXqAl3yjdnH4gxdoDgMJdOSEApO9Kcre1r2SEP8gZ5CKO4vndcxFwgG6fcVi4Olet_6mTgvkFyOgZZIjY-_DhKEie7BxwWTm6J_TB5Y8BmfHP8p-fru7HL3obn49P589-aiMVLp0mw5cBCaGcXFuO2M3XYt01Z3o2019mAVql6MduqNtp3puUTbKyWMtRpwVPKUvDz4LinWoLkMs8sGvYeAcc1D2yveqq6r4PP_wOu4plCzDZLztuO9VLxSzYEyKeac0A5Lqm2nm4Gz4XbF4Z8VK__s6LqOM0539HG2qr846pANeJtqoy7fYaKu3HIt_wD7Gqd-</recordid><startdate>19971001</startdate><enddate>19971001</enddate><creator>KÜFFERLE, B</creator><creator>TAUSCHER, J</creator><creator>ASENBAUM, S</creator><creator>VESELY, C</creator><creator>PODREKA, I</creator><creator>BRÜCKE, T</creator><creator>KASPER, S</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>19971001</creationdate><title>IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol</title><author>KÜFFERLE, B ; TAUSCHER, J ; ASENBAUM, S ; VESELY, C ; PODREKA, I ; BRÜCKE, T ; KASPER, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c345t-61a1a250c412b68cf68705f58bf75e9af4e492bfd9c5f8c913ef9442cff5aeb43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Antipsychotic Agents - pharmacokinetics</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotics</topic><topic>Benzamides</topic><topic>Biological and medical sciences</topic><topic>Clozapine</topic><topic>Clozapine - pharmacokinetics</topic><topic>Clozapine - therapeutic use</topic><topic>Computed tomography</topic><topic>Dibenzothiazepines - pharmacokinetics</topic><topic>Dibenzothiazepines - therapeutic use</topic><topic>Dopamine</topic><topic>Dopamine Antagonists - pharmacokinetics</topic><topic>Dopamine Antagonists - therapeutic use</topic><topic>Dopamine D2 receptors</topic><topic>Extrapyramidal system</topic><topic>Female</topic><topic>Haloperidol</topic><topic>Haloperidol - pharmacokinetics</topic><topic>Haloperidol - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neostriatum</topic><topic>Neostriatum - anatomy & histology</topic><topic>Neostriatum - metabolism</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychosis</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Psychotic Disorders - metabolism</topic><topic>Psychotropic drugs</topic><topic>Pyrrolidines</topic><topic>Quetiapine</topic><topic>Quetiapine Fumarate</topic><topic>Receptors, Dopamine D2 - metabolism</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - metabolism</topic><topic>Single photon emission computed tomography</topic><topic>Tomography, Emission-Computed, Single-Photon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KÜFFERLE, B</creatorcontrib><creatorcontrib>TAUSCHER, J</creatorcontrib><creatorcontrib>ASENBAUM, S</creatorcontrib><creatorcontrib>VESELY, C</creatorcontrib><creatorcontrib>PODREKA, I</creatorcontrib><creatorcontrib>BRÜCKE, T</creatorcontrib><creatorcontrib>KASPER, S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Psychopharmacologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KÜFFERLE, B</au><au>TAUSCHER, J</au><au>ASENBAUM, S</au><au>VESELY, C</au><au>PODREKA, I</au><au>BRÜCKE, T</au><au>KASPER, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol</atitle><jtitle>Psychopharmacologia</jtitle><addtitle>Psychopharmacology (Berl)</addtitle><date>1997-10-01</date><risdate>1997</risdate><volume>133</volume><issue>4</issue><spage>323</spage><epage>328</epage><pages>323-328</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><coden>PSYPAG</coden><abstract>We investigated the striatal dopamine-2 (D2) receptor occupancy caused by different antipsychotic substances in 18 psychotic patients (16 with schizophrenic and two with schizoaffective disorder according to DSM-IV) with single photon emission computed tomography (SPECT) using 123I-iodobenzamide (IBZM) as tracer substance. Four patients were treated with the novel antipsychotic compound quetiapine (300-700 mg/day), six with clozapine (300-600 mg/ day) and eight with haloperidol (10-20 mg/day). They were compared with eight healthy controls. Measurement of S/F ratios and consecutive calculation of D2 receptor occupancy revealed a significantly lower striatal D2 occupancy rate with quetiapine and clozapine in comparison to haloperidol. In correspondence with the low striatal D2 receptor occupancy rates and again in contrast to the haloperidol treatment group, there were no extrapyramidal motor side-effects (EPS) in the quetiapine and clozapine treatment groups. Therefore, the reported data support the position that quetiapine can be considered to be an atypical antipsychotic substance due to its relatively weak striatal D2 receptor blocking property and therefore its low propensity to induce EPS.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>9372530</pmid><doi>10.1007/s002130050409</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0033-3158 |
| ispartof | Psychopharmacologia, 1997-10, Vol.133 (4), p.323-328 |
| issn | 0033-3158 1432-2072 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79417488 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Antipsychotic Agents - pharmacokinetics Antipsychotic Agents - therapeutic use Antipsychotics Benzamides Biological and medical sciences Clozapine Clozapine - pharmacokinetics Clozapine - therapeutic use Computed tomography Dibenzothiazepines - pharmacokinetics Dibenzothiazepines - therapeutic use Dopamine Dopamine Antagonists - pharmacokinetics Dopamine Antagonists - therapeutic use Dopamine D2 receptors Extrapyramidal system Female Haloperidol Haloperidol - pharmacokinetics Haloperidol - therapeutic use Humans Male Medical sciences Middle Aged Neostriatum Neostriatum - anatomy & histology Neostriatum - metabolism Neuropharmacology Pharmacology. Drug treatments Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Psychosis Psychotic Disorders - drug therapy Psychotic Disorders - metabolism Psychotropic drugs Pyrrolidines Quetiapine Quetiapine Fumarate Receptors, Dopamine D2 - metabolism Schizophrenia - drug therapy Schizophrenia - metabolism Single photon emission computed tomography Tomography, Emission-Computed, Single-Photon |
| title | IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T06%3A18%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IBZM%20SPECT%20imaging%20of%20striatal%20dopamine-2%20receptors%20in%20psychotic%20patients%20treated%20with%20the%20novel%20antipsychotic%20substance%20quetiapine%20in%20comparison%20to%20clozapine%20and%20haloperidol&rft.jtitle=Psychopharmacologia&rft.au=K%C3%9CFFERLE,%20B&rft.date=1997-10-01&rft.volume=133&rft.issue=4&rft.spage=323&rft.epage=328&rft.pages=323-328&rft.issn=0033-3158&rft.eissn=1432-2072&rft.coden=PSYPAG&rft_id=info:doi/10.1007/s002130050409&rft_dat=%3Cproquest_cross%3E3117819341%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3117819341&rft_id=info:pmid/9372530&rfr_iscdi=true |